For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and ...
A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing ...
Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader ...
CAR-T therapy, which transformed the treatment of B-cell blood cancers, is now being tested as a way to reset the immune system in severe ...
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those ...
INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial / allogeneic ...
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results